# Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

> **NCT01263483** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 230 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin and voglibose
- **DRUG:** Alogliptin and voglibose
- **DRUG:** Voglibose

## Key facts

- **NCT ID:** NCT01263483
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263483, "Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01263483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*